Show simple item record

dc.contributor.authorNordby, Yngve
dc.contributor.authorRichardsen, Elin
dc.contributor.authorRakaee, Mehrdad
dc.contributor.authorNess, Nora
dc.contributor.authorDønnem, Tom
dc.contributor.authorPatel, Hitendra R.H.
dc.contributor.authorBusund, Lill-Tove
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorAndersen, Sigve
dc.date.accessioned2017-03-21T10:25:37Z
dc.date.available2017-03-21T10:25:37Z
dc.date.issued2017-02-24
dc.description.abstractDue to a lack of sufficient diagnostic tools to predict aggressive disease, there is a significant overtreatment of patients with prostate cancer. Platelet derived growth factors (PDGFs) and their receptors (PDGFRs) are key regulators of mesenchymal cells in the tumor microenvironment, and has been associated with unfavorable outcome in several other cancers. Herein, we aimed to investigate the prognostic impact of PDGFR-β and its ligands (PDGF-B and PDGF-D) in a multicenter prostatectomy cohort of 535 Norwegian patients. Using tissue microarrays and immunohistochemistry, the expression of ligands PDGF-B and PDGF-D and their corresponding receptor, PDGFR-β, was assessed in neoplastic tissue and tumor-associated stroma. PDGFR-β was expressed in benign and tumor associated stroma, but not in epithelium. High stromal expression of PDGFR-β was independently associated with clinical relapse (HR = 2.17, p = 0.010) and biochemical failure (HR = 1.58, p = 0.002). This large study highlights the prognostic importance of PDGFR-β expression, implicating its involvement in prostate cancer progression even in early stage disease. Hence, analyses of PDGFR-β may help distinguish which patients will benefit from radical treatment, and since PDGFR-β is associated with relapse and shorter survival, it mandates a focus as a therapeutic target.en_US
dc.descriptionSource: <a href=http://dx.doi.org/10.1038/srep43378>doi: 10.1038/srep43378</a>en_US
dc.identifier.citationNordby, Y. et al. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence. Sci. Rep. 7, 43378; doi: 10.1038/srep43378 (2017).en_US
dc.identifier.cristinIDFRIDAID 1459661
dc.identifier.doi10.1038/srep43378
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10037/10792
dc.language.isoengen_US
dc.publisherNature Publishing Groupen_US
dc.relation.journalScientific Reports
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleHigh expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrenceen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record